Prepared Remarks:

Operator

Good day, everyone, and welcome to the Seagen fourth quarter and full year 2022 conference call. [Operator instructions] Please also note, today's event is being recorded. At this time, I'd like to turn the conference call over to Doug Maffei, vice president, investor relations. Sir, please go ahead.

Doug Maffei -- Vice President, Investor Relations

Thank you, operator, and good afternoon, everyone. I'm pleased to welcome you to Seagen's fourth quarter 2022 financial results conference call. This afternoon, we issued a press release with our results. The press release and supporting slides are available on our website in the investors section, events, and presentations page.

In this call will be David Epstein, chief executive officer; Chip Romp, executive vice president, commercial U.S.; Todd Simpson, chief financial officer; and Roger Dansey, president of research and development. Following our prepared remarks, we'll open the line for questions. We aim to keep this call to one hour and ask that you limit yourself to one question to give everyone an opportunity to participate in Q&A during our call today. Today's conference call will include forward-looking statements regarding future or anticipated events and results, including the company's 2023 financial outlook, anticipated products, used costs and expenses, potential clinical and regulatory milestones, including data readouts and regulatory submissions, potential marketing approvals, and commercial performance.

Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the difficulty in forecasting sales, revenues, costs, and expenses and the uncertainty associated with the pharmaceutical development and regulatory approval process. More information about the risks and uncertainties faced by Seagen is contained under the caption Risk Factors included in the company's quarterly report for the quarter ended September 30th, 2022, filed with the Securities and Exchange Commission and the company's subsequent reports filed with the SEC. Now I'll turn the call over to David.

David Epstein -- Chief Executive Officer

Thank you, Doug, and good afternoon, everyone. Today, we reported total 2022 revenue of nearly $2 billion, reflecting 25% growth over 2021. This included record net product sales of $1.7 billion, driven by meaningful uptick across our entire commercial portfolio. Our sales guidance for '23 reflects our optimism in our ability to gain market share in existing indications and grow into newly labeled indications.